Dynavax Technologies’ (DVAX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a $29.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Dynavax Technologies’ Q4 2024 earnings at $0.04 EPS, FY2024 earnings at $0.18 EPS and FY2025 earnings at $0.26 EPS.

Separately, The Goldman Sachs Group reduced their price target on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Stock Up 5.0 %

DVAX stock opened at $13.66 on Friday. The stock has a market cap of $1.79 billion, a PE ratio of 105.01 and a beta of 1.34. The firm’s 50-day simple moving average is $11.16 and its 200 day simple moving average is $11.24. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $15.01. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Mizuho Markets Americas LLC raised its stake in Dynavax Technologies by 16.9% during the 1st quarter. Mizuho Markets Americas LLC now owns 852,057 shares of the biopharmaceutical company’s stock valued at $10,574,000 after purchasing an additional 123,300 shares during the period. Assenagon Asset Management S.A. acquired a new position in Dynavax Technologies during the third quarter valued at $8,291,000. Millennium Management LLC purchased a new stake in Dynavax Technologies in the 2nd quarter worth about $17,615,000. Vanguard Group Inc. boosted its position in Dynavax Technologies by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock worth $116,682,000 after acquiring an additional 126,458 shares during the period. Finally, Bank of Montreal Can grew its stake in Dynavax Technologies by 15.2% during the 2nd quarter. Bank of Montreal Can now owns 994,632 shares of the biopharmaceutical company’s stock valued at $11,309,000 after acquiring an additional 130,893 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.